论文部分内容阅读
肿瘤标记方面近年有很大进展,尤其是单克隆抗体的研究。现就肿瘤临床标记作一介绍。胎儿蛋白1.胰癌胎儿蛋白(POA),系胎儿胰腺与胰癌患者共同具有的血清蛋白。岛野氏等从胰癌患者的腹水中又分离出胰癌相关抗原(PCAA)。POA 与PCAA 仅存在于正常的粘液细胞中,而不存在于正常胰腺。放射免疫法(RIA)测定,血清中正常值:POAllunit/ml,PCAA22.3μg/ml。血清中 POA 有随年龄增大而升高之势。胰癌患者 POA 与 PCAA 的阳性率为48～75%,早期胰癌阳性率低,随病情发展而升高。岛野氏报告这
There have been great advances in tumor markers in recent years, especially the study of monoclonal antibodies. Now we will introduce the clinical markers of cancer. Fetal protein 1. Pancreatic cancer Fetal protein (POA) is a serum protein shared by fetal pancreas and pancreatic cancer patients. Shimano et al isolated pancreatic cancer-associated antigen (PCAA) from the ascites of pancreatic cancer patients. POA and PCAA are present only in normal mucinous cells but not in normal pancreas. As determined by radioimmunoassay (RIA), normal values in serum: POAllunit/ml, PCAA 22.3 μg/ml. POA in serum has a tendency to increase with age. The positive rate of POA and PCAA in patients with pancreatic cancer is 48 to 75%. The early positive rate of pancreatic cancer is low and increases with the progression of the disease. Shimano reports this